Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2016 1
2017 6
2018 3
2019 1
2020 4
2021 2
2022 2
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Improving Definition of Screen-Printed Functional Materials for Sensing Application.
Campos-Arias L, Peřinka N, Lau YC, Castro N, Pereira N, Correia VMG, Costa P, Vilas-Vilela JL, Lanceros-Mendez S. Campos-Arias L, et al. Among authors: castro n. ACS Appl Electron Mater. 2024 Apr 5;6(4):2152-2160. doi: 10.1021/acsaelm.3c01415. eCollection 2024 Apr 23. ACS Appl Electron Mater. 2024. PMID: 38680726 Free PMC article.
Treatment outcomes in classic Hodgkin lymphoma: 5-year update from the Brazilian Hodgkin Lymphoma Registry.
Biasoli I, Castro N, Colaço Villarim C, Traina F, Chiattone CS, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Buccheri V, Bonamin Sola C, de Oliveira de Paula E Silva R, Ribas AC, Steffenello G, Pagnano K, Soares A, de Souza C, Spector N. Biasoli I, et al. Among authors: castro n. EJHaem. 2023 Oct 4;4(4):1191-1195. doi: 10.1002/jha2.804. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024602 Free PMC article. No abstract available.
Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry.
Goveia L, Castro N, de Souza C, Colaço Villarim C, Traina F, Chiattone CS, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Buccheri V, Bonamin Sola C, de Oliveira Paula E Silva R, Ribas AC, Steffenello G, Pagnano K, Soares A, Souza Medina S, Silveira T, Zattar Cecyn K, Carvalho Palma L, de Oliveira Marques M, Spector N, Biasoli I. Goveia L, et al. Among authors: castro n. Ann Hematol. 2023 Oct;102(10):2815-2822. doi: 10.1007/s00277-023-05352-w. Epub 2023 Jul 21. Ann Hematol. 2023. PMID: 37474632
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, Martin T, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Dimopoulos MA, et al. Among authors: castro n. Am J Hematol. 2023 Jan;98(1):E15-E19. doi: 10.1002/ajh.26602. Epub 2022 Jun 4. Am J Hematol. 2023. PMID: 35604280 Free PMC article. No abstract available.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
21 results